Abacavir/Lamivudine 600mg
| Product Overview | |
| Generic Name | Abacavir/Lamivudine 600mg |
| Brand Name(s) | Kivexa, Epzicom, Abec L, Abalam, ABEC‑L |
| Form | 30 Film-coated oral tablets |
| Strength | 600 mg abacavir + 300 mg lamivudine per tablet |
| Therapeutic Class | Dual nucleoside reverse transcriptase inhibitors (NRTIs) |
| ATC Code | J05AR02 |
| Manufacturing & Regulatory | |
| Manufacturer | Taj Pharma, Emcure, Hetero Healthcare, PV Pharma, Privet Pharma, Azista |
| Country | India/USA/EU/Mexico |
| GMP Compliance | WHO‑GMP |
| DMF/CEP | Type II |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 10 pks |
| Shelf Life | 24 Months |
| Storage | Store below 25–30 °C in a dry place |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Provided per batch |
| SDS | Available standard API/excipient safety data sheets |
| CTD Summary | ACTD/CTD available from manufacturer upon significant commercial request |
Description
Indications & Usage: This fixed-dose combination is indicated for the treatment of HIV‑1 infection in adults and children weighing ≥25 kg. It combines two NRTIs, which inhibit HIV reverse transcriptase, reducing viral replication. Not to be used in patients with HLA‑B*5701 due to hypersensitivity risk. Typically part of first-line antiretroviral regimens, but requires caution in hepatic/renal impairment. Listed on the WHO Model List of Essential Medicines
